In heart failure with reduced ejection fraction (HFrEF) patients receiving ENTRESTO therapy, NT-proBNP will decrease, mimicking clinical improvement in the patient. BNP will tend to increase in response to this therapy, despite clinical improvement.
Laboratorians and physicians should understand the net effect of ENTRESTO on natriuretic peptides. Complete the form below and click Continue to access an FAQ document.
